Medicus Pharma to Present at BIO-Europe 2026
Medicus Chief Medical Officer Dr. Faisal Mehmud will address precision oncology and the Teverelix program at the Cologne conference.
Updated on Nov. 5, 2026 in Biotech
Medicus Pharma Ltd. (NASDAQ: MDCX) will present at BIO-Europe 2026 in Cologne, Germany, with a talk by Chief Medical Officer Dr. Faisal Mehmud on November 9, 2026. The presentation will cover progress in precision oncology, the development and partnership outlook for the Teverelix program, and related programs.
Why it matters
The presentation gives investors and prospective partners an update on the company's clinical priorities, including early-stage antibody-drug conjugate CD228V. Dr. Mehmud will also hold one-on-one meetings with institutional investors and potential partners during the conference.
The presentation is a company-scheduled 15-minute slot in Theatre B at Koelnmesse, with the Teverelix Phase program potentially shrinking from 1,500 to 600 patients. Clinical proof-of-concept for CD228V in melanoma has not yet been reported, and partner terms remain undisclosed.
The players
Medicus Pharma Ltd.
Medicus Pharma is a biotech company listed on NASDAQ under the ticker MDCX, focused on precision oncology and next-generation therapies.
Dr. Faisal Mehmud
Dr. Faisal Mehmud is the Chief Medical Officer of Medicus Pharma, who will deliver the company's conference presentation and meet with investors.
The details
Medicus will present through Dr. Mehmud, who will cover progress in precision oncology, including CD228V, an early-stage antibody-drug conjugate using Pfizer's vedotin linker-payload platform, and SkinJect, an investigational localized immuno-oncology product for basal cell carcinoma in patients with Gorlin syndrome. The company is prioritizing clinical proof-of-concept for CD228V in melanoma and intends to pursue partnerships that contribute expertise and development resources.
Timeline
November 9, 2026: Dr. Mehmud presents from 9:15 to 9:30 a.m. CET in Theatre B at Koelnmesse, Cologne.
November 9-11, 2026: BIO-Europe 2026 takes place in Cologne, Germany.
End of 2026: Anticipated completion of GMP-grade manufacturing and clinical readiness steps for Teverelix.
Industry Positioning
Medicus's CD228V program builds on Pfizer's established vedotin linker-payload platform, applying an existing antibody-drug conjugate architecture to the CD228 target in melanoma. The company's pursuit of partnerships reflects the broader pattern among small-cap biotechs of relying on external collaborators to fund late-stage development.
Readers following Medicus Pharma can use the conference presentation to track whether the company reports measurable clinical progress for CD228V in melanoma. Investors should watch for any announced partnerships, since the company has said it intends to pursue them to fund development.
The takeaway
Investors tracking early-stage oncology names should watch conference presentations like this one for concrete clinical milestones rather than general pipeline commentary. Partnership announcements tied to the Teverelix and CD228V programs will be the next meaningful signal of how the company plans to fund development.
What happens next
Dr. Mehmud's scheduled presentation at BIO-Europe 2026 takes place on November 9, 2026, from 9:15 to 9:30 a.m. CET in Theatre B at Koelnmesse, Cologne.
Further reading
Explore more Biotech coverage for context on pipeline development and clinical trends.
Source note: This article includes information reported by The Manila times.
